Lipocine Financial Statements From 2010 to 2021

Lipocine financial statements provide useful quarterly and yearly information to potential Lipocine investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on Lipocine financial statements helps investors assess Lipocine's valuation, profitability, and current liquidity needs.
We have found eighty available fundamental ratios for Lipocine, which can be analyzed and compared to other ratios and to its peers in the industry. We recommend to check Lipocine's last-minute fundamental drivers against the all of the trends between 2010 and 2021.
Lipocine Working Capital is quite stable at the moment as compared to the past year. The company's current value of Working Capital is estimated at 22.16 Million.

Lipocine Financial Statements 

 
Refresh
Check Lipocine financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Lipocine main balance sheet or income statement drivers, such as Gross Profit of 152.4 K, Interest Expense of 446.3 K or Operating Expenses of 17.4 M, as well as many exotic indicators such as Long Term Debt to Equity of 0.76, PPandE Turnover of 11.93 or Receivables Turnover of 9.39. Lipocine financial statements analysis is a perfect complement when working with Lipocine Valuation or Volatility modules. It can also supplement various Lipocine Technical models. Check out Stocks Correlation.

Lipocine Revenues

152,398Share

Lipocine Balance Sheet

Current ValueLast YearHistorical Average 10 Year Trend
Total Assets27.4 M25.4 M22.6 M
Increasing
Slightly volatile
Cash and Equivalents22 M24.2 M15.1 M
Increasing
Stable
Investments461.8 K450 K16.7 M
Decreasing
Slightly volatile
Investments Current461.8 K450 K16.5 M
Decreasing
Slightly volatile
Investments Non Current358.1 K360.2 K393.4 K
Decreasing
Slightly volatile
Property Plant and Equipment Net3.3 K3.2 K44.5 K
Decreasing
Slightly volatile
Trade and Non Trade Receivables3.4 K3.4 K3.7 K
Decreasing
Slightly volatile
Trade and Non Trade Payables1.4 M1.6 M994.6 K
Increasing
Slightly volatile
Total Liabilities8.1 M10 M4.8 M
Increasing
Slightly volatile
Shareholders Equity16.3 M15.3 M17.6 M
Increasing
Very volatile
Current Assets27.4 M25.3 M22.5 M
Increasing
Slightly volatile
Assets Non Current24.4 K23.8 K109.4 K
Decreasing
Stable
Current Liabilities5.2 M6.6 MM
Increasing
Slightly volatile
Liabilities Non Current4.5 M3.4 M4.8 M
Increasing
Slightly volatile
Tax Liabilities49.3 K49.5 K54.1 K
Decreasing
Slightly volatile
Total Debt6.2 M5.6 M9.3 M
Decreasing
Slightly volatile
Debt CurrentMM3.3 M
Decreasing
Slightly volatile
Debt Non CurrentM2.3 MM
Decreasing
Slightly volatile
Shareholders Equity USD16.3 M15.3 M17.6 M
Increasing
Very volatile
Cash and Equivalents USD22 M24.2 M15.1 M
Increasing
Stable
Total Debt USD6.2 M5.6 M9.3 M
Decreasing
Slightly volatile
Accounts Payable972 K1.1 M904.2 K
Increasing
Slightly volatile
Receivables19.5 K19 K85.2 K
Decreasing
Slightly volatile

Lipocine Income Statement

Current ValueLast YearHistorical Average 10 Year Trend
Revenues152.4 K148.5 K2.2 M
Decreasing
Slightly volatile
Selling General and Administrative Expense7.6 M8.2 M5.3 M
Increasing
Slightly volatile
Research and Development Expense10.2 M9.7 M7.7 M
Increasing
Slightly volatile
Operating Expenses17.4 M18 M12.8 M
Increasing
Slightly volatile
Interest Expense446.3 K386.6 K708.4 K
Decreasing
Slightly volatile
Income Tax Expense248230(4.1 K)
Increasing
Stable
Consolidated Income(21.5 M)(21 M)(12.7 M)
Decreasing
Slightly volatile
Net Income(21.5 M)(21 M)(12.7 M)
Decreasing
Slightly volatile
Net Income Common Stock(21.5 M)(21 M)(12.7 M)
Decreasing
Slightly volatile
Weighted Average Shares60.1 M55.7 M20.5 M
Increasing
Slightly volatile
Weighted Average Shares Diluted60.1 M55.7 M20.5 M
Increasing
Slightly volatile
Earning Before Interest and Taxes EBIT(22.2 M)(20.6 M)(12.7 M)
Decreasing
Slightly volatile
Revenues USD152.4 K148.5 K2.2 M
Decreasing
Slightly volatile
Net Income Common Stock USD(21.5 M)(21 M)(12.7 M)
Decreasing
Slightly volatile
Earning Before Interest and Taxes USD(22.2 M)(20.6 M)(12.7 M)
Decreasing
Slightly volatile
Gross Profit152.4 K148.5 K2.2 M
Decreasing
Slightly volatile
Operating Income(19.4 M)(18 M)(12.3 M)
Decreasing
Slightly volatile

Lipocine Cash Flow Statement

Current ValueLast YearHistorical Average 10 Year Trend
Net Cash Flow Investment Acquisitions and Disposals4.2 M3.9 M(10.1 M)
Increasing
Slightly volatile
Net Cash Flow from Financing17.3 M20.9 M16.7 M
Decreasing
Very volatile
Issuance Repayment of Debt Securities (1.5 M)(1.4 M)M
Decreasing
Slightly volatile
Issuance Purchase of Equity Shares17.8 M22.3 M16.3 M
Decreasing
Very volatile
Net Cash Flow from Investing4.2 M3.9 M303.7 K
Increasing
Stable
Net Cash Flow or Change in Cash and Cash Equivalents10.2 M9.5 M2.2 M
Increasing
Very volatile
Share Based Compensation1.6 M1.4 M1.2 M
Increasing
Slightly volatile
Depreciation Amortization and Accretion3.6 K3.6 K24.4 K
Decreasing
Slightly volatile

Financial Ratios

Current ValueLast YearHistorical Average 10 Year Trend
Earnings per Basic Share(0.41)(0.38)(0.4609)
Decreasing
Slightly volatile
Earnings per Diluted Share(0.41)(0.38)(0.4609)
Decreasing
Slightly volatile
Earnings per Basic Share USD(0.41)(0.38)(0.4609)
Decreasing
Slightly volatile
Return on Average Equity(1.74)(1.695)(0.0109)
Decreasing
Slightly volatile
Return on Average Assets(0.91)(0.887)0.2123
Decreasing
Slightly volatile
Return on Invested Capital(5.1)(4.723)(117)
Increasing
Slightly volatile
Gross Margin0.890.90.9829
Decreasing
Slightly volatile
Profit Margin(72.82)(70.95)(32.0452)
Decreasing
Slightly volatile
EBITDA Margin(68.44)(66.69)(30.9061)
Decreasing
Slightly volatile
Return on Sales(68.53)(66.77)(30.9506)
Decreasing
Slightly volatile
Asset Turnover0.00740.00721.3876
Decreasing
Slightly volatile
Sales per Share0.00550.00540.4439
Decreasing
Slightly volatile
Price to Sales Ratio54.9754.3462.779
Decreasing
Slightly volatile
Price to Book Value5.025.8233.1743
Increasing
Slightly volatile
Debt to Equity Ratio0.630.6530.4861
Increasing
Slightly volatile
Current Ratio3.953.84711.7735
Decreasing
Slightly volatile
Book Value per Share0.280.2751.2947
Decreasing
Stable
Tangible Assets Book Value per Share0.470.4551.4928
Decreasing
Stable
Total Assets Per Share0.620.61.322
Decreasing
Stable
Receivables Turnover9.396.912.2834
Decreasing
Slightly volatile
PPandE Turnover11.9313.1710.1365
Increasing
Slightly volatile
Cash and Equivalents Turnover0.02180.02130.062
Decreasing
Slightly volatile
Accounts Payable Turnover0.160.160.1577
Increasing
Slightly volatile
Accrued Expenses Turnover0.440.410.424
Decreasing
Slightly volatile
Long Term Debt to Equity0.760.70.7227
Decreasing
Stable
Quick Ratio3.353.2612.5442
Decreasing
Slightly volatile
Net Current Assets as percentage of Total Assets72.4467.14(88.6781)
Increasing
Stable
Revenue to Assets0.01350.00970.018
Decreasing
Slightly volatile

Lipocine Valuation Data

Current ValueLast YearHistorical Average 10 Year Trend
Earnings before Tax(21.5 M)(21 M)(12.7 M)
Decreasing
Slightly volatile
Earnings Before Interest Taxes and Depreciation Amortization EBITDA(22.2 M)(20.6 M)(12.6 M)
Decreasing
Slightly volatile
Earnings Before Interest Taxes and Depreciation Amortization USD(22.2 M)(20.6 M)(12.6 M)
Decreasing
Slightly volatile
Market Capitalization81.8 M89.3 M84.8 M
Decreasing
Stable
Enterprise Value69.4 M77.8 M64.4 M
Decreasing
Very volatile
Invested Capital145.8 K142.1 K6.4 M
Increasing
Stable
Average Equity15.1 M12.4 M16.8 M
Increasing
Stable
Average Assets27.1 M23.6 M21.5 M
Increasing
Slightly volatile
Invested Capital Average4.5 M4.4 M7.5 M
Increasing
Slightly volatile
Tangible Asset Value27.4 M25.4 M22.6 M
Increasing
Slightly volatile
Working Capital22.2 M18.7 M19.5 M
Increasing
Stable
Revenue Per Employee24.7 K15.8 K36.6 K
Decreasing
Slightly volatile

Lipocine Fundamental Market Drivers

Short Percent Of Float4.29%
Forward Price Earnings5.74
Shares Short Prior Month3.5M
Average Daily Volume Last 10 Day586.88k
Average Daily Volume In Three Month807.18k
Date Short Interest13th of August 2021
Fifty Day Average1.1091
Two Hundred Day Average1.3477

Lipocine Upcoming Events

Upcoming Quarterly Report10th of March 2022
Next Earnings Report5th of May 2022
Next Fiscal Quarter End31st of December 2021
Next Fiscal Year End10th of March 2022
Last Quarter Report30th of September 2021
Last Earning Announcement31st of December 2020

Be your own money manager

Our tools can tell you how much better you can do entering a position in Lipocine without increasing your portfolio risk or giving up expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate.risk-adjusted returns of your individual positions relative to your overall portfolio.

Did you try this?

Run Portfolio Diagnostics Now

   

Portfolio Diagnostics

Use generated alerts and portfolio events aggregator to diagnose current holdings
All  Next Launch Module

Becoming a Better Investor with Macroaxis

Macroaxis puts the power of mathematics on your side. We analyze your portfolios and positions such as Lipocine using complex mathematical models and algorithms, but make them easy to understand. There is no real person involved in your portfolio analysis. We perform a number of calculations to compute absolute and relative portfolio volatility, correlation between your assets, value at risk, expected return as well as over 100 different fundamental and technical indicators.

Build Optimal Portfolios

Align your risk with return expectations

Fix your portfolio
By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations
Check out Stocks Correlation. Note that the Lipocine information on this page should be used as a complementary analysis to other Lipocine's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Companies Directory module to evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals.

Other Tools for Lipocine Stock

When running Lipocine price analysis, check to measure Lipocine's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Lipocine is operating at the current time. Most of Lipocine's value examination focuses on studying past and present price action to predict the probability of Lipocine's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Lipocine's price. Additionally, you may evaluate how the addition of Lipocine to your portfolios can decrease your overall portfolio volatility.
Competition Analyzer
Analyze and compare many basic indicators for a group of related or unrelated entities
Go
Correlation Analysis
Reduce portfolio risk simply by holding instruments which are not perfectly correlated
Go
ETF Directory
Find actively traded Exchange Traded Funds (ETF) from around the world
Go
Transaction History
View history of all your transactions and understand their impact on performance
Go
Headlines Timeline
Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity
Go
Pair Correlation
Compare performance and examine fundamental relationship between any two equity instruments
Go
Price Ceiling Movement
Calculate and plot Price Ceiling Movement for different equity instruments
Go